Verseau Therapeutics

company

About

Verseau focus is building a pipeline of first-in-class therapies that modulate macrophages to trigger a coordinated immune attack on cancer.

  • 1 - 10

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$50M
Industries
Biotechnology,Therapeutics
Founded date
Jan 1, 2017
Number Of Employee
1 - 10
Operating Status
Active

Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. The company's modulators identify novel targets and develop therapies that shift macrophages between immune activators and silencers in disease, enabling physicians to benefit patients from immunotherapy.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$50M
Verseau Therapeutics has raised a total of $50M in funding over 2 rounds. Their latest funding was raised on Oct 21, 2019 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 21, 2019 Series Unknown $50M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Verseau Therapeutics is funded by 2 investors. InHarv Partners and 3sbio are the most recent investors.
Investor Name Lead Investor Funding Round
InHarv Partners Series Unknown
3sbio Series Unknown